Detection of Carbapenemases in Clinical Enterobacteriaceae Isolates Using the VITEK AST-N202 Card by �씠寃쎌썝 & �젙�꽍�썕
Infection & 
Chemotherapyhttp://dx.doi.org/10.3947/ic.2015.47.3.167Infect Chemother 2015;47(3):167-174
ISSN 2093-2340 (Print) · ISSN 2092-6448 (Online)
Received: May 12, 2015   Revised: June 2, 2015  Accepted: June 3, 2015
Corresponding Author : Seok Hoon Jeong, MD, PhD
Department of Laboratory Medicine and Research Institute of Bacterial Resistance, 
Yonsei University College of Medicine, 211 Eonjuro, Gangnam-gu, Seoul 06273, 
Korea
Tel: +82-2-2228-2448, Fax: +82-2-313-0956
E-mail: kscpjsh@yuhs.ac
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License 
(http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and repro-
duction in any medium, provided the original work is properly cited.
Copyrights © 2015 by The Korean Society of Infectious Diseases | Korean Society for Chemotherapy
www.icjournal.org
Detection of Carbapenemases in Clinical 
Enterobacteriaceae Isolates Using the VITEK 
AST-N202 Card
Il Kwon Bae1, Hyun-Kyung Kang1, In-Ho Jang2, Woonhyoung Lee3, Keonhan Kim4,  
Jung Ok Kim4, Seok Hoon Jeong4, and Kyungwon Lee4
1Department of Dental Hygiene, Silla University, Busan; 2Department of Biomedical Laboratory Science, College of Health Sciences, 
Sangji University, Wonju, Gangwon; 3Department of Laboratory Medicine, Kosin University College of Medicine, Busan; 4Department of 
Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Korea
Background: The rapid and accurate detection of carbapenemase-producing Enterobacteriaceae (CPE) in clinical microbiology labo-
ratories is essential for the treatment and control of infections caused by these microorganisms. This study was performed to evaluate 
the ability of the VITEK AST-N202 card to detect CPE isolates.
Materials and Methods: A total of 43 (Klebsiella pneumoniae, n = 37; Escherichia coli, n = 3; and Enterobacter cloacae, n = 3) CPE 
isolates and 79 carbapenemase-non-producing Enterobacteriaceae (CNE) isolates were included in this study. The CPE isolates har-
bored KPC-2 (n = 11), KPC-3 (n = 20), GES-5 (n = 5), VIM-2 (n = 2), IMP-1 (n = 1), NDM-1 (n = 2), or OXA-232 (n = 2). Of the 79 
CNE isolates, eight K. pneumoniae isolates were resistant to ertapenem, imipenem, and meropenem, while the remaining 71 isolates 
were susceptible to the carbapenems. Antimicrobial susceptibilities were tested using the VITEK AST-N202 card, and the results were 
interpreted as positive when the isolates showed resistant or intermediate results. Modified-Hodge tests (MHTs) were performed 
using ertapenem or meropenem disks for the screening of carbapenemase production. Polymerase chain reaction (PCR) and direct 
sequencing were used to identify β-lactamase genes.
Results: Sensitivity of MHT with ertapenem and meropenem disks for the detection of carbapenemase was 81.4% (35/43) and 81.4% 
(35/43), respectively, and a combination with both antibiotic disks increased the sensitivity to 88.4% (38/43). Specificity of the MHT 
was 100% (79/79) for the CNE isolates. Sensitivity of ertapenem, imipenem, and meropenem as assessed by the VITEK AST-N202 
card was 100% (43/43), 93% (40/43), and 95.3% (41/43), respectively. Specificity (89.8%, 71/79) of the test with each carbapenem 
was improved to 100% (71/71) when eight carbapenem-resistant CNE isolates were excluded from the testing.
Conclusion: The VITEK AST-N202 card showed high sensitivity for the detection of carbapenemases in Enterobacteriaceae 
strains. PCR and sequencing experiments for the detection of carbapenemases are recommended when clinical Enterobacteria-
ceae isolates show non-susceptibility to carbapenems.
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Introduction
Carbapenems have been used as the drug of choice for the 
treatment of infections caused by multi-drug resistant 
Gram-negative rods because these drugs easily permeate the 
porins of outer cellular membranes, exhibit high affinity with 
penicillin-binding proteins, and are stable against various 
β-lactamases produced by Gram-negative rods [1-4]. Howev-
er, carbapenem-resistant Enterobacteriaceae (CRE) has ap-
peared as a consequence of the frequent use of these drugs for 
the treatment of widespread extended-spectrum β-lactamase- 
and/or AmpC β-lactamase-producing Enterobacteriaceae [5]. 
Dissemination of CRE is considered a serious clinical threat 
because available antimicrobials for the treatment of infec-
tions caused by CRE are very limited.
Although Enterobacteriaceae can acquire carbapenem resis-
tance via various mechanisms, the most important one is the 
production of plasmid-mediated carbapenemases [5]. Diverse 
types of carbapenemases have appeared in Enterobacteriace-
ae, including 1) KPC- and GES-type enzymes belonging to 
class A, 2) IMP-, VIM-, and NDM-type metallo-β-lactamases 
(MBLs) belonging to class B, and 3) OXA-48 and its variants 
belonging to class D. Enterobacteriaceae strains producing 
these various carbapenemases have already appeared in Ko-
rea [6].
The rapid and accurate detection of carbapenemase-pro-
ducing Enterobacteriaceae (CPE) in clinical laboratories is es-
sential for the treatment of infections and infection control. 
However, the identification of CPE strains can be difficult be-
cause some CPE clinical isolates exhibit low-level resistance 
or susceptibility to carbapenems [7]. This study was per-
formed to evaluate the ability of VITEK AST-N202 cards 
(bioMérieux, Marcy l’Etoile, France) to reliably detect CPE 
strains isolated from a clinical setting.
Materials and Methods
1. Bacterial strains and susceptibility testing
A total of 122 Enterobacteriaceae clinical isolates, 43 CPE 
and 79 carbapenemase-non-producing Enterobacteriaceae 
(CNE), were included in this study (Table 1). The CPE clinical 
isolates were identified as follows: 37 Klebsiella pneumoniae, 
three Escherichia coli, and three Enterobacter cloacae. The 
CPE clinical isolates produced KPC-2 (n = 11), KPC-3 (n = 20), 
GES-5 (n = 5), VIM-2 (n = 2), IMP-1 (n = 1), NDM-1 (n = 2), and 
OXA-232 (n = 2) carbapenemases. Of the 79 CNE clinical iso-
lates, eight K. pneumoniae isolates were resistant to ertapen-
em, imipenem, and meropenem, while the remaining 71 iso-
lates were susceptible to these carbapenems; E. coli (n = 35), 
K. pneumoniae (n = 17), Klebsiella oxytoca (n = 1), E. cloacae 
(n = 1), Enterobacter aerogenes (n = 6), Enterobacter asburiae 
(n = 2), Serratia marcescens (n = 4), Citrobacter freundii (n = 1), 
Citrobacter koseri (n = 1), Morganella morganii (n = 2), and 
Proteus mirabilis (n = 1). Bacterial species were identified us-
ing matrix-assisted laser desorption/ionization-time of flight 
mass spectrometry (MALDI-TOF MS) (Bruker Daltonics, Bre-
men, Germany) and by analysis of partial 16S rDNA sequences. 
Antimicrobial susceptibilities of the clinical isolates were de-
termined using VITEK AST-N202 cards (bioMérieux, Table 2). 
Genes encoding β-lactamases, including TEM-, SHV-, CTX-M-, 
GES-, and KPC-types of class A; IMP-, VIM-, and NDM-types 
Table 1. Characteristics of carbapenem-resistant Enterobacteriaceae 
Strain
β-Lactamase Modified-Hodge test Antimicrobial susceptibilitya
Carbapenemase Others Ertapenem Meropenem Ertapenem Imipenem Meropenem
Klebsiella  
pneumoniae
KPC-2 SHV-12, SHV-1, TEM-1 + + R R R
KPC-2 SHV-12, SHV-1, TEM-1 + + R R R
KPC-2 SHV-12, SHV-1, TEM-1 + + R R R
KPC-2 SHV-12, SHV-1, TEM-1 + + R R R
KPC-2 SHV-12, SHV-1, TEM-1 + + R R R
KPC-2 SHV-12, SHV-11 + - R R R
KPC-2 SHV-11, TEM-1 + + R R R
KPC-2 TEM-1 + + R R R
KPC-2 - + R R R
KPC-2 + + R R R
KPC-2 + - R R R
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Table 1. Continued
Strain
β-Lactamase Modified-Hodge test Antimicrobial susceptibilitya
Carbapenemase Others Ertapenem Meropenem Ertapenem Imipenem Meropenem
Klebsiella 
pneumoniae
KPC-3 SHV-12, TEM-1, CMY-2 + + R R R
KPC-3 SHV-12, SHV-1, TEM-1 + + R R R
KPC-3 SHV-12, SHV-1, TEM-1 + + R R R
KPC-3 SHV-12, SHV-1, TEM-1 + + R R R
KPC-3 SHV-12, SHV-1, TEM-1 + - R R R
KPC-3 SHV-12, SHV-1, TEM-1 + + R R R
KPC-3 SHV-12, SHV-1, TEM-1 + + R R R
KPC-3 SHV-12, SHV-1, TEM-1 + + R R R
KPC-3 SHV-12, SHV-1, TEM-1 + + R R R
KPC-3 SHV-12, SHV-1, TEM-1 + + R R R
KPC-3 SHV-12, SHV-1, TEM-1 + + R R R
KPC-3 SHV-12, SHV-1, TEM-1 + + R R R
KPC-3 SHV-12, SHV-1, TEM-1 + + R R R
KPC-3 SHV-12, SHV-1, TEM-1 + + R R R
KPC-3 SHV-12, SHV-1, TEM-1 + + R R R
KPC-3 TEM-1 + + R R R
KPC-3 + + R R R
KPC-3 + + R R R
KPC-3 + + R R R
KPC-3 + + R R R
GES-5 SHV-12 + + R R R
GES-5 SHV-12 + + R R R
GES-5 SHV-12 - + R I R
GES-5 SHV-12, CMY-2 - - R I R
NDM-1 - + R R R
NDM-1 　 + + R R R
Escherichia 
coli
GES-5 - - R S S
OXA-232 + + R S R
OXA-232 　 - - R S S
Enterobacter 
cloacae
VIM-2 - - R R R
VIM-2 - - R R R
IMP-1 　 + + R R R
Klebsiella 
pneumoniae
CTX-M-3, SHV-12, DHA-1, 
TEM-1
- - R R R
CTX-M-14, SHV-2a, DHA-1 - - R R R
CTX-M-14, SHV-12, DHA-1 - - R R R
CTX-M-15, DHA-1 - - R R R
SHV-12, DHA-1 - - R R R
DHA-1 - - R R R
DHA-1 - - R R R
　 SHV-1, CMY-1 - - R R R
aAntimicrobial susceptibility was tested using the VITEK AST-N202 card.
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Table 2. Carbapenem disk contents of the VITEK AST-N202 card
Carbapenem 
disk
Indication 
MIC
(μg/mL)
MIC interpretive criteria
(μg/mL) FDA indication for use
Susceptible Resistance
Ertapenem 0.5, 1, 6 0.5  8 E. coli , K. pneumonia, Citrobacter freundii , Citrobacter koseri ,  
Enterobacter aerogenes, E. cloacae, Koxa (-ESBL), Morganella morganii , 
Proteus mirabilis , Proteus vulgaris , S. marcescens
Imipenem 1, 2, 6, 12  0.25 16 Acinetobacter spp., Citrobacter spp., Enterobacter spp., E. coli ,  
Klebsiella spp., M. morganii , P. vulgaris , Providencia rettgeri ,  
P. aeruginosa, S. marcescens, Providencia stuartii
Meropenem 0.5, 2, 6, 12  0.25 16 E. coli , K. pneumoniae, P. aeruginosa, P. mirabilis , Acinetobacter spp.,  
C. freundii , E. cloacae, K. oxytoca, M. morganii , P. vulgaris , S. marcescens, 
Aeromonas hydrophila, Citrobacter diversus, Hafnia alvei ,  
Pasteurella multocida, Salmonella spp., Shigella spp.
aKlebsiella oxytoca  (excluding ESBL-producing strains)
MIC, minimal inhibitory concentration; FDA, Food and Drug Administration; ESBL, extended-spectrum β-lactamase.
Table 3. Nucleotide sequences of primers used in this study
Primer name Target gene Nucleotide sequence (5’ to 3’) Product size (bp) Reference
KPC-F KPC-type GTCACTGTATCGCCGTCTAGTTC 909 This study
KPC-R TGGTGGGCCAATAGATGATT
GES-F GES-type CGCTTCATTCACGCACTATT 855 [8]
GES-R GTCCGTGCTCAGGATGAGTT
IMP-1F IMP-1 variants AAGGCGTTTATGTTCATACTTCG 605 This study
IMP-1R TTTAACCGCCTGCTCTAATGTAA
VIM-2F VIM-2 variants ATCATGGCTATTGCGAGTCC 749 [9]
VIM-2R ACGACTGAGCGATTTGTGTG
NDM-F NDM-type GCCCAATATTATGCACCCGG 738 This study
NDM-R CTCATCACGATCATGCTGGC
OXA-48F OXA-48 variants GATTATCGGAATGCCTGCGG 845 [10]
OXA-48R CTACAAGCGCATCGAGCATCA
TEM-F TEM-type CTTGAAGACGAAAGGGCCTC 997 [11]
TEM-R TGACTCCCCGTCGTGTAGAT
SHV-F SHV-type CGCCGGGTTATTCTTATTTG 936 This study
SHV-R CGGCTTAGCGTTGCCAGT
CTXM-1F CTXM-1 variants CCGTCACGCTGTTGTTAGG 782 [8]
CTXM-1R ACGGCTTTCTGCCTTAGGTT
CTXM-9F CTXM-9 variants CAAAGAGAGTGCAACGGATG 862 [8]
CTXM-9R CCTTCGGCGATGATTCTC
CMY-1F CMY-1 variants CAACGACAATCCATCCTGTG 1,007 This study
CMY-1R GAGCCGGTCTTGTTGAAGAG
CMY-2F CMY-2 variants AGTAAGACGTTTAACGGCGTGT 749
CMY-2R TTATGCACCCATGAGGCTTT
DHA-F DHA type ACAATCGCCACCTGTTTTTC 976 This study
DHA-R TGGTGGACAGCACCATTAAA
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of class B; CMY-1-, CMY-2-, and DHA-types of class C; and 
OXA-48-types of class D, were identified by PCR and sequenc-
ing (Table 3) [8-11].
2. Detection of carbapenemases
Carbapenemases were screened using VITEK AST-N202 
cards and modified Hodge tests (MHTs). If an isolate exhibit-
ed intermediate or resistance designations to more than one 
of the carbapenems, ertapenem, imipenem, or meropenem, 
based on the VITEK AST-N202 card, then the isolate was con-
sidered CPE. MHTs were performed with ertapenem and 
meropenem disks, separately, as described previously [12]. 
Briefly, a suspension of E. coli ATCC 25922 at a 0.5 McFarland 
turbidity unit concentration was spread on the entire surface 
of a MacConkey agar (Becton and Dickinson Company, 
Sparks, MD, USA) plate. Disks containing ertapenem or mero-
penem (10 μL, Becton and Dickinson Company) were placed 
on the center of the agar using a cotton swab, and then the 
clinical isolates were thickly inoculated from the edge of the 
disk to the periphery of the agar using a platinum loop. After 
overnight incubation, if a thickening of the inoculation line of 
a clinical isolate was observed on the edge of an inhibition 
zone, then the isolate was considered a CPE strain.
Results
1. Ability of MHTs to identify CPE strains
Of the 43 CPE isolates, 35 (81.4%) exhibited positive results 
in the MHTs with ertapenem or meropenem disks. In the er-
tapenem MHTs, eight CPE isolates showed false-negative re-
sults, including KPC-2-producing K. pneumoniae (n = 1), 
GES-5-producing K. pneumoniae (n = 2), NDM-1-producing K. 
pneumoniae  (n = 1), GES-5-producing E. coli  (n = 1), 
OXA-232-producing E. coli (n = 1), and VIM-2-producing E. 
cloacae (n = 2). In the meropenem MHTs, eight CPE isolates 
showed false-negative results, including KPC-2-producing K. 
pneumoniae (n = 2), KPC-3-producing K. pneumoniae (n = 1), 
GES-5-producing K. pneumoniae (n = 1), GES-5-producing E. 
coli (n = 1), OXA-232-producing E. coli (n = 1), and VIM-2-pro-
ducing E. cloacae (n = 2). Five CPE isolates showed false-neg-
ative results in both ertapenem and meropenem MHTs, in-
c l u d i n g  G E S - 5 -p r o d u c i n g  K .  p n e u m o n i a e  ( n  =  1 ) , 
GES-5-producing E. coli (n = 1), OXA-232-producing E. coli (n 
= 1), and VIM-2-producing E. cloacae (n = 2). All 79 CNE iso-
lates showed negative results regardless of carbapenem sus-
ceptibility. Sensitivities of the ertapenem and meropenem 
MHTs for CPE were both 81.4% (35/43), and that was in-
creased to 88.4% (38/43) when the MHTs were performed 
with both antibiotics. Specificity of the MHTs was 100% 
(79/79) (Table 4).
2. Ability of the VITEK AST-N202 card to identify 
CPE strains
In antimicrobial susceptibility testing using VITEK 
AST-N202 cards, all 43 CPE isolates exhibited resistance to er-
tapenem, while only 38 and 41 of the CPE isolates showed re-
sistance to imipenem and meropenem, respectively. Two and 
three CPE isolates exhibited intermediate and susceptibility 
patterns to imipenem, respectively, and two isolates were sus-
ceptible to meropenem. Three isolates exhibiting susceptibili-
ty patterns to imipenem included one GES-5-producing E. coli 
isolate and two OXA-232-producing E. coli isolates. Two iso-
lates exhibited susceptibility to meropenem, including one 
GES-5-producing E. coli isolate and one OXA-232-producing 
E. coli isolate. Of the 79 CNE isolates, eight exhibited resis-
tance to ertapenem, imipenem, and meropenem, while the 
remaining 71 isolates were susceptible to these carbapenems. 
Sensitivities to ertapenem, imipenem, and meropenem of the 
CPE strains when assessed using the VITEK AST-N202 cards 
were 100% (43/43), 88.4% (38/43), and 95.3% (41/43), respec-
tively. Sensitivity of the VITEK 2 AST-N202 cards for the CPE 
Table 4. Sensitivity and specificity of modified-Hodge test and VITEK AST-N202 cards for the detection of CPE strains
Methods Antimicrobial agent (s) Sensitivity Specificity
Modified-Hodge test Ertapenem    81.4% (35/43) 100% (79/79)
Meropenem    81.4% (35/43)
Ertapenem + meropenem    88.4% (38/43)
VITEK AST-N202 card Ertapenem 100.0% (43/43)  89.9% (71/79)a
Meropenem    95.3% (41/43)
Imipenem    93.0% (40/43)
CPE, carbapenemase-producing enterobacteriaceae.
aThe results of eight carbapenem-resistant clinical CRE isolates are excluded.
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strains when using all three carbapenems was 100%. Specific-
ities of the three carbapenems for CPE strains using the VITEK 
AST-N202 cards were all 89.8% (71/79); however, that reached 
100% (71/71) when the eight carbapenem-resistant clinical 
CNE isolates were excluded (Table 4).
Discussion
Although the prevalence of CPE strains is still low (<1%) in 
Korea, various types of carbapenemases have been identified 
(Table 4). Since the first isolation of S. marcescens-producing 
class B VIM-2 MBL in Korea in 2002, VIM-2-producing E. cloa-
cae have repeatedly been reported (Table 5) [13-25]. An out-
break of NDM-1-producing K. pneumoniae sequence type 340 
(ST340) was reported in 2012, and the NDM-1-producing E. 
coli ST101 strain appeared in Korea in 2013 [26]. In a nation-
wide survey of antimicrobial resistance performed in 2003, a 
class A GES-5 carbapenemase was first identified in two clini-
cal K. pneumoniae isolates from a hospital in Gyeonggi prov-
ince, and an outbreak caused by the strain occurred in that 
same hospital in the next year [19]. Furthermore, a GES-5-pro-
ducing E. coli ST131 was detected in 2011 [18]. An infection 
caused by the KPC-2-producing K. pneumoniae ST11 strain 
was first reported in 2010; thereafter, outbreaks caused by the 
KPC-2-producing K. pneumonia ST258 strain have been re-
peatedly reported in several hospitals in Korea [13, 14]. In 
2014, an outbreak caused by K. pneumoniae ST14-producing 
OXA-232, a variant of class D OXA-48, occurred in a hospital 
in Seoul, Korea, and E. coli isolates producing this carbapene-
mase were also detected from rectal swab specimens [25]. 
Therefore, the development of rapid and accurate methods for 
the detection of CPE is needed for adequate treatment of in-
fections caused by these microorganisms and for prevention 
of further dissemination.
Recently, the Clinical and Laboratory Standard Institute 
(CLSI) recommended MHTs with ertapenem disks as the 
standard detection method for CPE strains [12]. This study 
was performed to compare the ability of ertapenem and 
meropenem MHTs with VITEK AST-N202 cards. Both ertape-
nem and meropenem MHTs detected 35/43 (81.4%) CPE iso-
lates, and sensitivity was increased to 88.4% (38/43) when the 
MHTs were performed with both carbapenem disks. The re-
sults indicate that the detection of CPE strains is dependent 
on whether MHTs fail in some cases, especially in cases of 
CPE strains harboring carbapenemases (GES-5, OXA-232, and 
MBLs) other than KPC. Ertapenem susceptibility testing using 
the VITEK AST-N202 card detected all 43 CPE isolates as re-
sistant, while three and two CPE isolates respectively exhibit-
ed susceptibility patterns to imipenem and meropenem using 
this commercial card. CPE isolates harboring GES-5 or OXA-
232 exhibited susceptibility to these carbapenems. The results 
suggest that CPE detection must be conducted based on er-
tapenem susceptibility when using VITEK AST-N202 cards.
Table 5. Carbapenemase-producing Enterobacteriaceae in Korea
Carbapenemase Species Strain
MIC (μg/mL)
Reference
Imipenem Meropenem
KPC-2 K. pneumoniae KPN-DK2 16 16 [13]
KPC-2 K. pneumoniae KPN1010 >256 >256 [14]
KPC-2 K. pneumoniae 6 isolates 32-128 64-256 [15]
KPC-2 K. pneumoniae 3 isolates 2-4 2-16 [16]
KPC-2 K. pneumoniae MP14 ND ≥16 [17]
GES-5 K. pneumoniae 2 isolates ND ND [18]
GES-5 K. pneumoniae 6 isolates 0.5-1 ND [19]
GES-5 E. coli BD07372 0.5 0.25 [20]
VIM-2 S. marcescens YMC00/4/1591 64 64 [21]
VIM-2 E. cloacae KU680 4 4 [22]
VIM-2 E. cloacae YMC08/12/3793 4 0.75 [23]
VIM-2 E. cloacae YMC03/4/397 4 4 [23]
NDM-1 K. pneumoniae 4 isolates 1- >128 2- >128 [24]
OXA-232 E. coli
K. pneumoniae
2 isolates
16 isolates
1
4-16
0.5-1
8-16
[25]
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In conclusion, the VITEK AST-N202 card showed excellent 
performance for the detection of CPE strains. It is recom-
mended that ertapenem-resistant Enterobacteriaceae clinical 
isolates should be directly subjected to molecular diagnostic 
methods for the identification of carbapenemase genes, be-
cause MHTs did now show sufficient sensitivity for the detec-
tion of CPEs.
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